
Final Figures Distinguish Participation From Shares Tendered
PolyPeptide said the 97.99% participation rate represents 32,458,892 shares in aggregate, combining shares validly tendered with shares already held by Samsung Peptide and parties acting in concert with it. By the close of the additional acceptance period on October 30, shareholders had validly tendered 32,350,302 shares. Those shares represented 97.98% of the shares covered by the offer and 97.66% of PolyPeptide's total issued share capital and voting rights. The difference between the three percentages reflects which shares each calculation counts and the share base against which they are measured.
Cash Offer Values PolyPeptide at Approximately CHF 1.46 Billion
Samsung Biologics announced the proposed acquisition in July at CHF 44.31 per share in cash, valuing PolyPeptide's fully diluted equity at approximately CHF 1.46 billion, excluding treasury shares. Samsung Peptide AG, the company's direct Swiss subsidiary, published the offer prospectus on August 31 for all publicly held registered shares. The November update confirms the final tender count after the additional acceptance period. The cash offer price and equity valuation describe the transaction terms, while the participation rate records the aggregate share position reported at the close of the offer.


Settlement Moves Beyond the Original November Date
The offer prospectus had indicated November 13, 2026, as the settlement date. Samsung postponed that date after reviewing the status of regulatory approval procedures in multiple jurisdictions. Its November 5 update placed expected completion toward the end of 2026 or in the first quarter of 2027. Samsung said it would announce a specific settlement date once all offer conditions have been fulfilled. After settlement, Samsung Peptide intends to pursue a squeeze-out of the remaining public shareholders and apply to delist PolyPeptide's shares from the SIX Swiss Exchange.
Acquisition Would Expand Samsung's Peptide Manufacturing Capabilities
PolyPeptide provides contract development and manufacturing services for peptide-based active pharmaceutical ingredients. Samsung Biologics has cited the Swiss company's specialized peptide expertise and international manufacturing network as reasons for the acquisition. The proposed combination would add those capabilities to Samsung's contract manufacturing portfolio and broaden the range of drug substance projects it can support. The definitive tender result settles how many shares were submitted under the offer. The next milestone for both companies and for customers following the transaction is confirmation of the settlement date.



